• Home
  • A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).

Author List
Amy Jo Chien, Siti Rahmaputri, Heidi F Dittrich, Melanie Catherine Majure, Hope S. Rugo, Michelle E. Melisko, Andrei Goga
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/79294069
Publication Year
2019
Publication Title
Amy Jo Chien, Siti Rahmaputri, Heidi F Dittrich, Melanie Catherine Majure, Hope S. Rugo, Michelle E. Melisko, Andrei Goga. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):1072-1072.